ARTICLE | Company News

Genetic Technologies diagnostic news

September 29, 2014 7:00 AM UTC

Genetic Technologies announced plans to restructure and realign activities to focus on the U.S. molecular diagnostics market and commercialization of its BREVAGen test. Genetic Technologies markets BREVAGen to determine an individual's risk of developing non-familial breast cancer in the U.S. BREVAGen -- a breast cancer stratification test that combines a DNA-based profile of breast cancer-associated SNPs with the patient's clinical history -- has CE Mark approval. Next month, Genetic Technologies plans to launch BREVAGenplus, the next-generation version of BREVAGen that extends the applicability of the test beyond the Caucasian population to include African-American and Hispanic women. ...